# Nuformix Plc, EMA Backs Orphan Status for NXP002 in Pulmonary Fibrosis Breakthrough (Video)

- Link: https://www.directorstalkinterviews.com/nuformix-plc-ema-backs-orphan-status-for-nxp002-in-pulmonary-fibrosis-breakthrough-video/4121194808
- Published: 2025-05-01T08:00:18+01:00
- Author: Emily Johnson

**Nuformix Plc** ([LON:NFX](https://www.directorstalkinterviews.com/company/nuformix-plc/nfx.l))
just secured a significant regulatory milestone. Europe’s EMA has issued a positive
opinion granting orphan drug designation for its lead asset NXP002 (Tranilast) in
idiopathic pulmonary fibrosis.

In this interview, Executive Director Dr Dan Gooding outlines how this validation
not only highlights the urgent unmet need in IPF but also sharpens Nuformix’s commercial
edge with 10 years of market exclusivity and accelerated development support. Investors
will want to hear how this development positions Nuformix for partnerships, progress
in the US, and wider clinical momentum.

Nuformix Plc is a UK-based pharmaceutical development company focused on repurposing
existing drugs to address serious unmet needs in fibrosis and oncology.

Share on:
